Pharmaceuticals News and Research

RSS

ISIS conducts phase 2 study of ISIS-SMNRx in infants with type I spinal muscular atrophy

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it dosed the first infant in the 12 mg dose group in the Phase 2 study evaluating ISIS-SMNRx in infants with Type I spinal muscular atrophy (SMA).

4 Oct 2013

J&J's Janssen Companies Launch A Trio Of Collaborations

...

3 Oct 2013

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.

3 Oct 2013

Global leading supplier of pharmaceutical commercial packaging solutions, PCI, announces expansion of its personnel by 50

Packaging Coordinators, Inc. (PCI) is a global leading supplier of pharmaceutical commercial packaging solutions and clinical trials services. This week, they have announced that over the next six months the company will be further expanding its personnel by 50 at its Hay-on-Wye site. This latest recruitment drive comes after a successful apprenticeship enrolment programme, and following the placement of four Undergraduates from Swansea University; reinforcing the company’s commitment to supporting the development and education of the local community. Since April 2013, PCI has already recruited 40 staff members within the life sciences sector, signaling itself as one of the principal employers within the Life Sciences/Biotech industry in Wales.

From Packaging Coordinators Inc. (PCI) 3 Oct 2013

Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial

Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients.

2 Oct 2013

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society in Dallas on Oct. 9-10.

2 Oct 2013

NIMH Awards Optivia $1.8M CNS Drug Development

...

2 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

2 Oct 2013

Digital security: an interview with Jon Edgcombe, leader of the software technologies group at Cambridge Consultants

Digital security is a key requirement in our product designs, especially in markets such as healthcare where the design is complete long before final regulatory approval. From a commercial point of view, ignoring data privacy, device authentication, and anti-counterfeit at design stage is no longer a tenable position for a connected product that produces sensitive patient data – even if it is nominally pseudonomised.

2 Oct 2013

Valeant Pharmaceuticals partners with NCADV to raise awareness of domestic violence

Valeant Pharmaceuticals International, Inc.announced a partnership with the National Coalition Against Domestic Violence to help raise awareness of domestic violence. As part of the new domestic violence initiative, Valeant has pledged to donate a portion of sales from all Medicis and Obagi products to the NCADV in support of its initiatives.

2 Oct 2013

Final patient completion of phase II study of TR040303 in patients treated for acute myocardial infarction announced by Trophos

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the final patient completion of a phase II study of TR040303 in patients treated for acute myocardial infarction (MI). Outcome data of this study is expected to be available towards the end of 2013.

2 Oct 2013

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

New data from Boehringer Ingelheim's hepatitis C virus clinical development program have been accepted for presentation at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 1-5 in Washington, D.C.

1 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

1 Oct 2013

FDA Approves Takeda-Lundbeck Drug For Major Depressive Disorder

...

1 Oct 2013

Merck & Co. Axes 8,500 In R&D Restructuring

...

1 Oct 2013

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

Haemtech Biopharma Services (HBS) is pleased to announce the successful validation of a thrombin generation assay (TGA) for an IVIG drug. The assay was validated in 2012 to support the use of TGA as a release assay for Biotest Pharmaceuticals Corporation's U.S. Food and Drug Administration Biologics License Application for BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] product. The validated TGA assay was designed and performed on the Calibrated Automated Thrombogram® platform (CAT) from Diagnostica Stago, Inc. (Parsippany, NJ).

1 Oct 2013

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases, through its subsidiary, and Intrexon Corporation, a leader in synthetic biology, today announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide.

1 Oct 2013

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma" by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology.

1 Oct 2013

New approaches needed for testing cancer drugs

Research institutes, regulators and the pharmaceutical industry are urged to cooperate to develop new approaches to testing cancer drugs, in order to bring the revolution in personalised medicine to patients across Europe, says the European Society for Medical Oncology.

1 Oct 2013

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced successful results from a large phase II clinical study of its ToleroMune® grass allergy treatment (Grass-Synthetic Peptide Immuno-Regulatory Epitope [Grass-SPIRE])

1 Oct 2013

Pharmaceuticals News and Research

ISIS conducts phase 2 study of ISIS-SMNRx in infants with type I spinal muscular atrophy

J&J's Janssen Companies Launch A Trio Of Collaborations

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

Global leading supplier of pharmaceutical commercial packaging solutions, PCI, announces expansion of its personnel by 50

Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

NIMH Awards Optivia $1.8M CNS Drug Development

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Digital security: an interview with Jon Edgcombe, leader of the software technologies group at Cambridge Consultants

Valeant Pharmaceuticals partners with NCADV to raise awareness of domestic violence

Final patient completion of phase II study of TR040303 in patients treated for acute myocardial infarction announced by Trophos

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

FDA Approves Takeda-Lundbeck Drug For Major Depressive Disorder

Merck & Co. Axes 8,500 In R&D Restructuring

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

New approaches needed for testing cancer drugs

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence